BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
+0.5%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$9.7B
AUM Growth
-$152M
(-1.5%)
Cap. Flow
+$254M
Cap. Flow
% of AUM
2.62%
Top 10 Holdings %
Top 10 Hldgs %
29.73%
Holding
233
New
14
Increased
60
Reduced
64
Closed
42
Top Buys
| 1 |
CareDx
CDNA
|
$65.3M |
| 2 |
Abbott
ABT
|
$50.4M |
| 3 |
Molina Healthcare
MOH
|
$46.5M |
| 4 |
Danaher
DHR
|
$44.5M |
| 5 |
Medtronic
MDT
|
$34M |
Top Sells
| 1 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
$63.1M |
| 2 |
Centene
CNC
|
$40.7M |
| 3 |
Baxter International
BAX
|
$40.6M |
| 4 |
Hologic
HOLX
|
$22.3M |
| 5 |
DexCom
DXCM
|
$15.4M |
Sector Composition
| 1 | Healthcare | 97.85% |
| 2 | Technology | 0.8% |
| 3 | Industrials | 0.75% |
| 4 | Communication Services | 0.02% |
| 5 | Energy | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Bristol-Myers Squibb
BMY
$95B
| $66.1M | 0.68% |
1,059,347
-243,587
| -19% | -$15.2M |
|
52
Thermo Fisher Scientific
TMO
$185B
| $65.6M | 0.68% |
98,328
+11,449
| +13% | +$7.64M |
|
53
Omnicell
OMCL
$1.52B
| $65.4M | 0.67% |
362,332
-31,251
| -8% | -$5.64M |
|
54
Nektar Therapeutics
NKTR
$684M
| $60.1M | 0.62% |
296,780
-9,530
| -3% | -$1.93M |
|
55
Regeneron Pharmaceuticals
REGN
$60.1B
| $58.8M | 0.61% |
93,060
-13,350
| -13% | -$8.43M |
|
56
Scholar Rock
SRRK
$3.12B
| $57M | 0.59% |
2,294,425
| – | – |
|
57
Cigna
CI
$81.2B
| $56.3M | 0.58% |
245,174
+27,362
| +13% | +$6.28M |
|
58
Penumbra
PEN
$10.9B
| $55.7M | 0.57% |
193,734
-11,958
| -6% | -$3.44M |
|
59
Adaptive Biotechnologies
ADPT
$1.98B
| $55.2M | 0.57% |
1,968,431
+632,408
| +47% | +$17.7M |
|
60
Globus Medical
GMED
$8.14B
| $54.7M | 0.56% |
757,464
+28,044
| +4% | +$2.02M |
|
|
61
Centene
CNC
$14.1B
| $54.4M | 0.56% |
660,010
-494,535
| -43% | -$40.7M |
|
|
ABMD
62
DELISTED
Abiomed Inc
ABMD
| $53.9M | 0.56% |
150,178
-1,000
| -0.7% | -$359K |
|
|
RDUS
63
DELISTED
Radius Health, Inc.
RDUS
| $53.8M | 0.55% |
7,768,714
| – | – |
|
64
Exelixis
EXEL
$10.1B
| $52.3M | 0.54% |
2,859,000
| – | – |
|
65
Exact Sciences
EXAS
$9.73B
| $50M | 0.52% |
642,582
+213,309
| +50% | +$16.6M |
|
66
Beam Therapeutics
BEAM
$1.88B
| $48.8M | 0.5% |
612,821
| – | – |
|
67
IQVIA
IQV
$31.3B
| $46.1M | 0.48% |
163,520
-27,100
| -14% | -$7.65M |
|
|
68
Hologic
HOLX
$14.8B
| $44.4M | 0.46% |
579,424
-291,238
| -33% | -$22.3M |
|
69
Halozyme
HALO
$8.59B
| $42.9M | 0.44% |
1,067,500
+146,000
| +16% | +$5.87M |
|
|
MTEM
70
DELISTED
Molecular Templates, Inc.
MTEM
| $42.6M | 0.44% |
725,200
| – | – |
|
71
Veeva Systems
VEEV
$44.3B
| $42.1M | 0.43% |
164,955
-9,596
| -5% | -$2.45M |
|
72
AbbVie
ABBV
$376B
| $41.6M | 0.43% |
306,900
+24,000
| +8% | +$3.25M |
|
|
SILK
73
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $40.6M | 0.42% |
952,433
+170,773
| +22% | +$7.28M |
|
|
HZNP
74
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $39.7M | 0.41% |
368,600
-47,600
| -11% | -$5.13M |
|
|
75
Baxter International
BAX
$12.1B
| $38.6M | 0.4% |
449,849
-473,374
| -51% | -$40.6M |
|